Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + cisplatin + 5-fluorouracil + filgrastim
- Development stage
- Unknown
- Lead developer
- Emory University
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
This neoadjuvant chemotherapy regimen, evaluated by Emory University, consists of paclitaxel (Taxol), cisplatin, and 5-fluorouracil (5-FU), administered alongside granulocyte colony-stimulating factor (G-CSF) support, typically filgrastim. Paclitaxel functions as a microtubule-stabilizing agent that inhibits mitosis, while cisplatin acts as a DNA-crosslinking platinum compound that induces apoptosis. 5-fluorouracil is an antimetabolite that targets thymidylate synthase to disrupt DNA synthesis. The addition of G-CSF is intended to mitigate the hematologic toxicity, specifically neutropenia, associated with this intensive triplet chemotherapy. This combination was investigated in a Phase II clinical trial for patients with resectable local-regional esophageal carcinoma to assess its efficacy in achieving pathological complete response and improving surgical outcomes.
- Other names
- Taxol, Cisplatin, 5-Fluorouracil, G-CSFTPF regimen + G-CSFEmory TPF regimen
02
Targets
TUBB (Tubulin (alpha and beta subunits))CSF3R (Granulocyte colony-stimulating factor receptor)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on paclitaxel + cisplatin + 5-fluorouracil + filgrastim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + cisplatin + 5-fluorouracil + filgrastim.